Selecta Biosciences Profit Margin 2015-2021 | SELB
Current and historical gross margin, operating margin and net profit margin for Selecta Biosciences (SELB) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Selecta Biosciences net profit margin as of June 30, 2021 is -95.56%.
|Selecta Biosciences Annual Profit Margins
|Selecta Biosciences Quarterly Profit Margins
||Medical - Biomedical and Genetics
Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States.